UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000017260
Receipt number R000020002
Scientific Title A study of the effect of long-term anticholinergic administration -solifenacin succinate-
Date of disclosure of the study information 2015/04/24
Last modified on 2015/04/23 22:36:54

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A study of the effect of long-term anticholinergic administration
-solifenacin succinate-

Acronym

A study of the effect of long-term anticholinergic administration

Scientific Title

A study of the effect of long-term anticholinergic administration
-solifenacin succinate-

Scientific Title:Acronym

A study of the effect of long-term anticholinergic administration

Region

Japan


Condition

Condition

overactive bladder

Classification by specialty

Urology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

We evaluate the usefulness after 52 weeks treatment with solifenacin succinate in OAB patients.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

We explore the factors that affect their usefulness in agent.

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Solifenacin succinate 5 mg will be orally administered once a day after breakfast for 52 weeks.

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1)OAB patients (urgency score (OABSS) >= 2 and OABSS total score >= 3)
2)Residual urine volume <100ml
3)Patients from whom we have received written consent.

Key exclusion criteria

1)Patients who has contraindication of solifenacin succinate
2)Patients with prostate cancer
3)Patients with dutrusor underactivity
4)Patients with history of urethral stricture
5)Patients with history of radiation therapy
6,7)Patients with bladder cancer, urinary tract stones, symptomatic urinary tract infection, recurrent urinary tract infection and interstitial cystitis.
8)Patients with using self catheterization
9)Patients with history of resistance to anti-holinergic agents
10)Any other patients who are regarded as unsuitable for this study by the investigator

Target sample size

100


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Hiroshi Tanaka

Organization

Hokkaido University Graduate School of Medicine

Division name

Department of Renal and Genitourinary surgery

Zip code


Address

North 15, West 7, Kita-ku, Sapporo, 060-8638, Japan

TEL

011-706-5966

Email

h-tanaka@med.hokudai.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Hiroshi Tanaka

Organization

Hokkaido University Graduate School of Medicine

Division name

Department of Renal and Genitourinary surgery

Zip code


Address

North 15, West 7, Kita-ku, Sapporo, 060-8638, Japan

TEL

011-706-5966

Homepage URL


Email

h-tanaka@med.hokudai.ac.jp


Sponsor or person

Institute

Hokkaido University Graduate School of Medicine

Institute

Department

Personal name



Funding Source

Organization

none

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2015 Year 04 Month 24 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2008 Year 11 Month 17 Day

Date of IRB


Anticipated trial start date

2008 Year 12 Month 07 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2015 Year 04 Month 23 Day

Last modified on

2015 Year 04 Month 23 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000020002


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name